Blog | BioInformant

Americord Registry Launches Pricing Calculator for Cord Blood Banking Services

October 13, 2016 By Cade Hildreth, Founder & President Leave a Comment

NEW YORK, New York — Americord, the fastest growing cord blood bank in the country, and a leader in the advancement of umbilical cord blood, cord tissue, and placenta tissue banking, announces the launch of its Cord Blood Banking Pricing Calculator. [Read more…]

Pall Corporation and RoosterBio to Co-Market Mesenchymal Stem/Stromal Cells and Bioreactors

October 5, 2016 By Cade Hildreth, Founder & President Leave a Comment

The agreement will encompass a co-development and marketing partnership.

RoosterBio, “Radically Changing the Use of Stem Cells”

OCTOBER 05, 2016 –Pall Corporation, a global leader in bioprocess equipment and disposables, announced the signing of a commercial collaboration agreement with RoosterBio Inc, an innovative adult stem cell technology company. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). [Read more…]

CDI Launches Opsis, Provia Expands Perinatal Storage, CCBC Gets Biologics License

September 28, 2016 By Cade Hildreth, Founder & President Leave a Comment

We have released coverage of this week’s stem cell industry activity that I am excited to share with you. It was a major week for stem cells, with CDI launching Opsis Therapeutics, Provia Laboratories expanding its stem cell product portfolio, CCBC getting a FDA Biologics License for CLEVECORD™, STEMCELL Technologies exploring genomic instability in an upcoming webinar, and iPSCs turning 10. [Read more…]

Provia Laboratories™ Expands its Stem Cell Portfolio to Amniotic Fluid, Chorionic Villi, and Placenta

September 28, 2016 By Cade Hildreth, Founder & President 1 Comment

Provia Laboratories, a leader in cGMP stem cell processing, banking and manufacturing, executed an agreement to license Biocell Group’s technology for processing stem cells from Amniotic Fluid, Chorionic Villi, and Placenta for the US and Asian markets.

[Read more…]

Cellular Dynamics International (CDI) Launches Opsis Therapeutics to Develop Cell Therapies for Retinal Diseases

September 28, 2016 By Cade Hildreth, Founder & President 2 Comments

MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]